Long-Term Tirzepatide Therapy Yields Significant Weight Loss and Cardiometabolic Benefits
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 9th, 2025
|
Obesity is closely linked to the development of type 2 diabetes, a condition marked by significant beta cell dysfunction and insulin resistance. Weight management—whether through pharmacological interventions or lifestyle changes—has been proven to lower the risk of diabetes. Numerous studies have highlighted the weight loss benefits of tirzepatide, and a study funded by Eli Lilly has explored its potential for treating obesity and preventing diabetes.
The phase 3 clinical trial enrolled 2,539 participants, with an average age of 48.2 years, all diagnosed with obesity and prediabetes. At baseline, the cohort had an average body weight of 107.3 kg and a BMI of 38.8. Biochemical assessments revealed mean levels of glycated hemoglobin at 5.76%, fasting glucose at 101.3 mg/dL, and insulin at 16.5 mIU/L. Participants were randomly assigned to receive either a placebo or tirzepatide at one of three dose levels: 5 mg, 10 mg, or 15 mg, administered via subcutaneous injection once weekly. Tirzepatide acts as an agonist by activating both the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which in turn stimulates insulin production from the pancreas and helps reduce appetite.
After 176 weeks of treatment, researchers observed that patients receiving tirzepatide experienced substantial weight loss. Specifically, those treated with a weekly dose of 15 mg achieved an average weight reduction of 20%, compared to only a 1.3% reduction in the placebo group. Additionally, tirzepatide was linked to a significantly lower risk of type 2 diabetes. Improvements were also noted in various cardiometabolic markers, including blood pressure, lipid profiles, and liver enzymes (ALT and AST), in the tirzepatide group.
The phase 3 clinical trial enrolled 2,539 participants, with an average age of 48.2 years, all diagnosed with obesity and prediabetes. At baseline, the cohort had an average body weight of 107.3 kg and a BMI of 38.8. Biochemical assessments revealed mean levels of glycated hemoglobin at 5.76%, fasting glucose at 101.3 mg/dL, and insulin at 16.5 mIU/L. Participants were randomly assigned to receive either a placebo or tirzepatide at one of three dose levels: 5 mg, 10 mg, or 15 mg, administered via subcutaneous injection once weekly. Tirzepatide acts as an agonist by activating both the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which in turn stimulates insulin production from the pancreas and helps reduce appetite.
After 176 weeks of treatment, researchers observed that patients receiving tirzepatide experienced substantial weight loss. Specifically, those treated with a weekly dose of 15 mg achieved an average weight reduction of 20%, compared to only a 1.3% reduction in the placebo group. Additionally, tirzepatide was linked to a significantly lower risk of type 2 diabetes. Improvements were also noted in various cardiometabolic markers, including blood pressure, lipid profiles, and liver enzymes (ALT and AST), in the tirzepatide group.